-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Propofol fumarate is a powerful antiviral drug for chronic hepatitis B in adults and adolescents, and is the same nucleoside (acid) drug as fumarate novovir dipropide (TDF) and ETV, and is listed as one of the top three first-line drugs in the global hepatitis B treatment guidelines.
,000-based propofol-nofovir tablet, developed by Gilead and called Vemlidy, is known as "the strongest hepatitis B drug in history."
2019, Vemlidy's global sales were $488 million, up 52.02 percent year-on-year.
's Vemlidy was approved to enter the domestic market in November 2018.
meters of intranet data show that in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal propofol for Nofowe sales of more than 30 million yuan.
fumarate propofol for the new classification of production of Novowe tablets Mienet data show that there are currently 16 pharmaceutical companies to copy 3 or imitation 4 categories to submit a fumarate propofol to nofowe tablets market application.
, Chengdu Bett Pharmaceuticals took the lead in September 23 into the administrative approval stage, October 19 successfully became the first imitation in China.
to date, Chengdu Bett Pharmaceuticals has 20 varieties (29 acceptance numbers) of generic drugs reported in the new classification reviewed and will be treated as if they had passed a consistency evaluation after being approved for production.
7 out of 20 varieties of new classified generics reviewed by Chengdu Pharmaceuticals have not been approved for sale in the domestic market, including Shakuba quercetin sodium tablets, hydrobrominate vositin tablets, and estalfeline phosphate Mixed suspension agent, methyl sulfonate lunvatini capsules, entourtabin propofol nofowei tablets, hydrochloric acid right metominated sodium chloride injection, cephalosporine particles, etc. , Chengdu Vit Pharmaceuticals will compete with a number of pharmaceutical companies for the first imitation.
source: MiNet database, State Drug Administration